Coverage your patients can count on:
IN 2019, FARXIGA® (dapagliflozin) STAYS PREFERRED* ON NATIONAL CAREMARK FORMULARY AT THE LOWEST BRANDED CO-PAY† FOR THE 4TH YEAR IN A ROW1-4
*”Preferred” means Tier 1, Tier 2, or Tier 3 when Tier 3 is the lowest branded tier.
AstraZeneca does not endorse any individual, commercial, Medicare Part D, or Medicaid plan or plans.
†Effective January 1, 2019, Jardiance® (empagliflozin) will also be Preferred/Lowest brand co-pay.1
1.CVS Caremark performance drug list - standard control. https://www.caremark.com/portal/asset/caremark_drug_list.pdf. Published November 2018. Accessed January 19, 2019.
2.CVS Caremark performance drug list. https://benefits.llnl.gov/content/assets/docs/OS-cvs-performance-drug-list.pdf. Published April 2016. Accessed September 18, 2018.
3.CVS Caremark performance drug list. http://media.mcclatchy.com/static/livewell/media/2017/cvs-caremark-drug-formulary.pdf. Published January 2017. Accessed September 18, 2018.
4.CVS Caremark performance drug list – standard control. https://www.caremark.com/portal/asset/caremark_drug_list.pdf. Published October 2017. Accessed September 18, 2018.
5.CVS Caremark formulary exclusion list. https://www.caremark.com/portal/asset/PA_Formulary_Exclusions_dl_OE.pdf. Published October 2018. Accessed November 28, 2018.
Invokana is a registered trademark of Janssen Pharmaceuticals, Inc.
Jardiance is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc.